LOG IN
 
 
E-mail Address
Password
Forgot your password? Click here to reset it

Request an Account

IN THE NEWS
 
 

RECENT NEWS FROM ALL OF OUR PORTFOLIO COMPANIES

January 6, 2016
Melinta Therapeutics Initiates Phase 3 Study of Baxdela in Hospital-Treated Community-Acquired Bacterial Pneumonia

January 5, 2016
Melinta Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference

October 9, 2015
Melinta Therapeutics Presents Complete Delafloxacin Results from Phase 3 Study in Patients with Acute Bacterial Skin and Skin Structure Infections at ID Week

October 5, 2015
ImmusanT Welcomes Michael Cooreman, M.D., Ph.D., as Chief Medical Officer and Anita Treohan as Director of Clinical Operations

September 20, 2015
Melinta Therapeutics Demonstrates Potency of Delafloxacin against Bacteria Associated with Respiratory Tract Infections

September 2, 2015
Journal Gastroenterology Publishes Research Indicating Nearly Identical Response to Gluten in Most Children and Adults with Celiac Disease

June 22, 2015
CVC Capital Partners, Temasek & Vatera Healthcare investment consortium to acquire controlling stake in Alvogen

June 10, 2015
Melinta Therapeutics Announces $67M Series 4 Financing

 
 
 

Alvogen

June 22, 2015
CVC Capital Partners, Temasek & Vatera Healthcare investment consortium to acquire controlling stake in Alvogen

Arisaph Pharmaceuticals

September 29, 2014
Arisaph Pharmaceuticals Awarded Supplemental Phase I And Phase II STTR Grants To Develop Oncology Drug Candidates

Edgemont Pharmaceuticals

December 3, 2014
IntelGenx Grants Extension of Marketing Exclusivity in the U.S. to Edgemont of Forfivo XL(R)

ImmusanT

October 5, 2015
ImmusanT Welcomes Michael Cooreman, M.D., Ph.D., as Chief Medical Officer and Anita Treohan as Director of Clinical Operations

September 2, 2015
Journal Gastroenterology Publishes Research Indicating Nearly Identical Response to Gluten in Most Children and Adults with Celiac Disease

December 22, 2014
ImmusanT Raises $12 Million in Series B Financing

November 20, 2014
Cambridge company recognized for potential Celiac-curing vaccine

November 19, 2014
ImmusanT’s Immunotherapy for Celiac Disease, Nexvax2, Selected as One of Informa’s Top 10 Autoimmune/Anti-Inflammatory Projects to Watch

Melinta Therapeutics

January 6, 2016
Melinta Therapeutics Initiates Phase 3 Study of Baxdela in Hospital-Treated Community-Acquired Bacterial Pneumonia

January 5, 2016
Melinta Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference

October 9, 2015
Melinta Therapeutics Presents Complete Delafloxacin Results from Phase 3 Study in Patients with Acute Bacterial Skin and Skin Structure Infections at ID Week

September 20, 2015
Melinta Therapeutics Demonstrates Potency of Delafloxacin against Bacteria Associated with Respiratory Tract Infections

June 10, 2015
Melinta Therapeutics Announces $67M Series 4 Financing

June 2, 2015
Melinta Therapeutics Joins White House Forum on Antibiotic Stewardship in Commitment to Take Steps to Avert Potential Crisis

May 19, 2015
Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients’ Recovery from Acute Bacterial Skin Infections

April 14, 2015
Melinta Therapeutics Announces Publication of an Independent Review of Delafloxacin Clinical Results and Pharmacokinetics

April 9, 2015
Melinta Therapeutics Shows that Health-Related Quality-of-Life is higher in ABSSSI Patients Deemed Cured vs Improved after End of Treatment

February 9, 2015
Melinta Therapeutics Secures up to $30 Million from Hercules Technology Growth Capital

January 8, 2015
Melinta Therapeutics and Eurofarma Laboratórios Enter into Commercialization and Distribution Agreements for Delafloxacin in Brazil

January 7, 2015
Melinta Therapeutics’ Lead Candidate Delafloxacin Yields Positive Top-Line Results in Phase 3 Study in Patients with ABSSSI

Pearl Therapeutics

March 18, 2015
AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD

June 10, 2013
Pearl Therapeutics to be Acquired by AstraZeneca for up to $1.15 Billion